FDA Commissioner Discusses Mifepristone Review

In a recent conversation with Politico’s Dasha Burn, Commissioner Marty McCurry shared his insights on Mifepristone, the abortion medication. He noted that he observes data indicating that patients sometimes take the drug outside the supervision of their healthcare providers.

During the interview, which is set to air completely on Sunday’s episode of Politico’s “Conversation,” McCurry explained the FDA’s ongoing review of Mifepristone’s safety. He emphasized that this review “was a requirement from previous administrators.” He acknowledged concerns about how women might be affected by “an imbalance in abusive power from men in their relationships,” suggesting this is a factor the FDA must consider.

He remarked, “You have to be open-minded at all times,” and underscored the importance of listening to differing opinions when making decisions. He said it was crucial for the FDA to engage with what’s happening in the field and ponder how they can contribute positively.

However, McCurry was clear that there’s no preset plan to alter the Mifepristone policy, particularly regarding telehealth services and mail orders. At the beginning of the interview, Burn pointed out that Senator Josh Hawley from Missouri has been exerting pressure on the FDA to limit access to Mifepristone via telehealth and mail.

In response to this, McCurry mentioned he doesn’t feel pressured by anyone, acknowledging the various public opinions on the matter. Recently, Senator Hawley introduced legislation aimed at reinstating safety regulations surrounding Mifepristone and highlighted previous research revealing significant side effects linked to abortion medications.

Furthermore, a recent investigation by the Daily Caller News Foundation revealed that Mifepristone could be ordered online without the need for a physician’s consultation. This raised concerns about the lack of face-to-face medical evaluation, ultrasound, or safety checks.

In light of these developments, McCurry stressed the FDA’s renewed dedication to drug safety, while also acknowledging the complexities involved in regulating medication access. Amid ongoing legal challenges—including a lawsuit alleging misinformation about abortion drugs by Planned Parenthood—the conversation about Mifepristone remains a contentious and evolving issue.